Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)

BackgroundCladribine tablets (marketed as Mavenclad) are a new oral therapy, which has recently been listed on the pharmaceutical benefits scheme in Australia for the treatment of relapsing multiple sclerosis (MS). The current dosing schedule is for 2 courses given a year apa...

Descrizione completa

Salvato in:

Dettagli Bibliografici
Autori principali:	Vicki E Maltby, Rodney A Lea, Mastura Monif, Marzena J Fabis-Pedrini, Katherine Buzzard, Tomas Kalincik, Allan G Kermode, Bruce Taylor, Suzanne Hodgkinson, Pamela McCombe, Helmut Butzkueven, Michael Barnett, Jeannette Lechner-Scott
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	JMIR Publications 2021-10-01
Serie:	JMIR Research Protocols
Accesso online:	https://www.researchprotocols.org/2021/10/e24969
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)

Documenti analoghi